UPDATE: Piper Jaffray Upgrades Celgene (CELG) to Overweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall St hits two-week lows as rising bond yields, Walmart results drag
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
Celgene (CELG) PT Lifted at Nomura Post Q1
April 25, 2014 7:48 AM EDTNomura Securities analyst M. Ian Somaiya reiterated a Buy rating on Celgene (NASDAQ: CELG) and boosted his price target to $252.00 (from $248.00) following Q1 results, saying buyback trumps seasonality.
Somaiya commented, "We are raising EPS estimates and target price to $252 from $248, as Celgene... More
Celgene Corp (CELG) Tops Q1 EPS by 2c
April 24, 2014 7:35 AM EDTCelgene Corp (NASDAQ: CELG) reported Q1 EPS of $1.67, $0.02 better than the analyst estimate of $1.65. Revenue for the quarter came in at $1.71 billion versus the consensus estimate of $1.77 billion.
Net Product Sales Performance
REVLIMID® sales for the first quarter increased 14 percent to $1,144 million and were driven by overall market share, increased duration of... More